Christoph Zapf
About Christoph Zapf
Christoph Zapf is the Executive Director and Head of Oncology Chemistry-West at Bristol Myers Squibb, with extensive experience in oncology chemistry and drug discovery.
Company
Christoph Zapf is currently employed at Bristol Myers Squibb. He holds the position of Executive Director and Head of Oncology Chemistry-West. He joined the company in April 2020. Bristol Myers Squibb is a leader in the field of immuno-oncology, focused on developing therapies to treat cancer patients.
Title
Christoph Zapf holds the executive role of Executive Director and Head of Oncology Chemistry-West at Bristol Myers Squibb. In this capacity, he leads a team dedicated to advancing oncology chemistry.
Education and Expertise
Christoph Zapf has an extensive educational background in chemistry. He studied at Friedrich-Alexander-Universität Erlangen-Nürnberg, where he achieved a Dipl.-Chem. in Chemistry from 1992 to 1998. He then earned a Ph.D. in Organic Chemistry from UC San Diego from 1998 to 2003. Additionally, he completed a Postdoc in Chemistry at Princeton University between 2003 and 2005. His expertise spans organic and medicinal chemistry, focusing on innovative therapeutic approaches.
Previous Positions
Before joining Bristol Myers Squibb, Christoph Zapf worked at Nurix Therapeutics as Executive Director for 8 months. Prior to that, he served as Director for a year and Associate Director for two years at the same company. He also spent several years at Pfizer, where he held various positions, including Senior Principal Scientist in Cambridge, Massachusetts, and multiple roles as a Principal Scientist and Senior Research Scientist.
Background
Christoph Zapf has a robust background in both academic and industrial research settings. His extensive experience includes significant roles at Pfizer, Nurix Therapeutics, and currently at Bristol Myers Squibb. His contributions in oncology chemistry are particularly noteworthy, focusing on the development of novel therapeutic approaches, including 'molecular glue' to target undruggable elements in the immuno-oncology field.